Trials / Completed
CompletedNCT00171990
Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,461 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This is a phase III, multicenter, randomized, double-blind, parallel-group study to compare the efficacy and safety of a two-day treatment with famciclovir (500 mg loading dose followed by 250 mg 12-hourly) to standard five-day treatment with famciclovir (125 mg 12-hourly) in patients with active recurrent genital herpes. This study is not recruiting patients in the United States.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Famciclovir |
Timeline
- Start date
- 2003-01-01
- Completion
- 2006-02-01
- First posted
- 2005-09-15
- Last updated
- 2013-08-15
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT00171990. Inclusion in this directory is not an endorsement.